Prothena Corporation plc

NASDAQ:PRTA

Biotechnology

Healthcare
$8.35 +3.89%

+$0.33 today

Market cap
$428.77M
Beta
-0.32
P/E (TTM)
-3.1
EPS (TTM)
-$2.81
52W Low $5.64High $11.80

Volume 0.76M

Average 0.51M

PRTA Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Prothena Corporation plcNASDAQ: PRTA

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses growth accelerates

Q1 FY2026 other income / expenses of $6.93M rose 64.7% year over year, ahead of the -10.8% change in trailing-twelve-month other income / expenses. Sequentially, it rose 23.1% from the prior quarter.

Context

  • Other income / expenses amounted to 168.0% of revenue in FY2025, up 149.0 pp from a year earlier.
  • Other income / expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +64.7% holds above the trailing-twelve-month pace of -10.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.93M+23.1% QoQ
Last fiscal yearDec 2025
-$16.27M-163.5% YoY
LTMMar 2026
$20.28M-10.8% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+64.7%——
1 year-163.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(16.27M) USD
Year-over-year change
-163.5%

Other Income / Expenses vs competitors

How PRTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -10.8% is the 3rd highest of 10, against a peer median of -45.3%.
  • Other income / expenses amounts to 35.0% of revenue for PRTA, versus a peer median of 39.8%.
PRTA Competitors
Other Income / Expenses for PRTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DNLIDenali Therapeutics Inc.LTM Jun 2026$31.35M USD-42.6%+42.7%869.8%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$23.26M USD+14.4%+3.1%—
PRTAProthena Corporation plcLTM Mar 2026$20.28M USD-10.8%—35.0%
ANNXAnnexon, Inc.LTM Mar 2026$8.58M USD-44.7%+38.6%—
AVXLAnavex Life Sciences Corp.LTM Dec 2025$4.67M USD-45.3%+14.3%—
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$1.34M USD-87.1%+1.6%—
PMNProMIS Neurosciences, Inc.LTM Jun 2026$1.21M USD-93.9%-95.6%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$745K USD-95.5%-4.3%—
ACIUAC Immune S.A.LTM Mar 2026-CHF 1.47M CHF-268.3%—39.8%
BIIBBiogen Inc.LTM Jun 2026-$415.9M USD+31.7%—4.2%
Peer median (excluding PRTA) —-45.3%+3.1%39.8%

Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue200.58M53.91M91.37M135.16M9.68M
Cost of Revenue00003.7M
Gross Profit200.58M53.91M91.37M135.16M5.98M
Gross Margin100.0%100.0%100.0%100.0%61.8%
Research & Development82.28M135.56M220.57M222.52M134.85M
Selling, General & Admin46.32M49.9M61.84M67.2M59.39M
Operating Expenses128.6M185.46M282.41M289.72M190.54M
Depreciation & Amortization1.12M744K928K893K3.7M
EBITDA73.04M(124.86M)(159.55M)(128.04M)(197.13M)
EBITDA Margin36.4%-231.6%-174.6%-94.7%-2035.6%
Operating Income71.98M(131.56M)(191.04M)(154.56M)(184.56M)
Operating Margin35.9%-244.1%-209.1%-114.4%-1905.8%
Interest Income42K6.35M31.01M25.82M14.14M
Interest Expense00000
Other Income / Expenses(54K)5.95M30.56M25.63M(16.27M)
Income Before Tax71.92M(125.61M)(160.48M)(128.93M)(200.83M)
Pre-Tax Margin35.9%-233.0%-175.6%-95.4%-2073.8%
Income Tax Expense4.95M(8.66M)(13.45M)(6.62M)43.26M
Net Income66.98M(116.95M)(147.03M)(122.31M)(244.09M)
Net Margin33.4%-217.0%-160.9%-90.5%-2520.6%
EPS (Basic)1.51(2.47)(2.76)(2.27)(4.53)
EPS (Diluted)1.38(2.47)(2.76)(2.27)(4.53)
Weighted Avg Shares44.23M47.37M53.22M53.77M53.83M
Weighted Avg Shares (Diluted)48.46M47.37M53.22M53.77M53.83M

Prothena Corporation plc

NASDAQ:PRTA

Intrinsic Alpha fair value

Locked

Current Price

$8.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.